26CA Stock Overview A clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
ImmunityBio, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for ImmunityBio Historical stock prices Current Share Price US$2.72 52 Week High US$9.21 52 Week Low US$2.44 Beta -0.26 1 Month Change -41.66% 3 Month Change -13.54% 1 Year Change -31.29% 3 Year Change -49.04% 5 Year Change n/a Change since IPO -90.11%
Recent News & Updates
Immunitybio, Inc. Announces Permanent J-Code (J9028) for Anktiva®? Is Now Effective Jan 07 ImmunityBio, Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million. Dec 12
ImmunityBio, Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.
ImmunityBio, Inc. Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Nov 20
Third quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 3Q 2023) Nov 13
ImmunityBio, Inc. Announces First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma Oct 25 See more updates
Immunitybio, Inc. Announces Permanent J-Code (J9028) for Anktiva®? Is Now Effective Jan 07 ImmunityBio, Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million. Dec 12
ImmunityBio, Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.
ImmunityBio, Inc. Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Nov 20
Third quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 3Q 2023) Nov 13
ImmunityBio, Inc. Announces First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma Oct 25
New major risk - Financial position Aug 19
Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.32 loss in 2Q 2023) Aug 13
ImmunityBio, Inc.'s ANKTIVA® Now Covered by More Than a Dozen Insurance Plans Representing over 100 Million Lives Within Months of FDA Approval Aug 13
ImmunityBio, Inc Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer Aug 06
ImmunityBio, Inc. Announces the Initial Treatment of Multiple Patients in the United States to Receive Therapy with ANKTIVA Jun 20
First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.27 loss in 1Q 2023) May 10
ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® May 09
ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024 May 01
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer Apr 26
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Apr 23
Insufficient new directors Apr 01
No longer forecast to breakeven Mar 26
New minor risk - Profitability Mar 25
Full year 2023 earnings released: US$1.15 loss per share (vs US$1.04 loss in FY 2022) Mar 20
ImmunityBio Announces Data from A Phase 1 Pilot Study Mar 06
ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial Feb 21
Forecast to breakeven in 2026 Feb 12
Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes (PROs) of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG Feb 05
New major risk - Financial position Nov 10
Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.28 loss in 3Q 2022) Nov 10
ImmunityBio, Inc. Announces First Data for Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-Tumor Activity Nov 08
ImmunityBio, Inc. Announces U.S. Food and Drug Administration Accepts its BLA Resubmission as Complete and Sets New PDUFA Date Oct 28
ImmunityBio, Inc. Announces Biological License Application Resubmission for N-803 in BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ Oct 24
New major risk - Shareholder dilution Sep 19 ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC Sep 13
ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC Sep 12
Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2022) Aug 09
Jakubowitz Law Reminds Immunitybio Shareholders of A Lead Plaintiff Deadline of August 29, 2023 Aug 05
ImmunityBio, Inc. Appoints Enrique Diloné as Chief Technology Officer, Effective August 14, 2023 Aug 04
ImmunityBio, Inc. Announces Findings from a Phase 1 Study Showing Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Jul 11
Pomerantz Law Firm Announces the Filing of a Class Action Against ImmunityBio, Inc. and Certain Officers – IBRX Jul 01
Independent Director recently bought €66k worth of stock Jun 06
ImmunityBio, Inc., Annual General Meeting, Jun 13, 2023 May 20
ImmunityBio, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration Regarding Its Biologics License Application May 12
First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.26 loss in 1Q 2022) May 12
Full year 2022 earnings released: US$1.04 loss per share (vs US$0.89 loss in FY 2021) Mar 03 ImmunityBio, Inc. announced that it expects to receive $50 million in funding Dec 14
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.22 loss in 3Q 2021) Nov 10
Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.23 loss in 2Q 2021) Aug 09
ImmunityBio, Inc. Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma in Situ Jul 29
ImmunityBio, Inc. Announces Quilt Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer Jun 07
ImmunityBio, Inc. Submits Biologics License Application for N-803 Plus Bcg for Patients with Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ May 24
First quarter 2022 earnings released: US$0.26 loss per share (vs US$0.21 loss in 1Q 2021) May 11
ImmunityBio, Inc., Annual General Meeting, Jun 14, 2022 May 02
High number of new directors Apr 27
Immunitybio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer Apr 26
ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer Mar 04
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 03
ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer Mar 03
ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX). Feb 16
ImmunityBio, Inc. Announces Positive Data from its Late-Stage Bladder Cancer Trial Feb 15
ImmunityBio, Inc. Announces Promising Clinical Study Results for Kick and Kill HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy Feb 01
ImmunityBio, Inc. Announces Interim Results in its Metastatic Pancreatic Cancer Trial Jan 19
ImmunityBio, Inc. Announces Updates on Its Clinical Year-End Review of Strategic Milestones Dec 21
Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.17 loss in 3Q 2020) Nov 15
ImmunityBio, Inc. Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with A Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-Free in Phase 2/3 Trial Sep 14
ImmunityBio, Inc. Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19 Jul 15 ImmunityBio, Inc.(NasdaqGS:IBRX) dropped from Russell 3000E Growth Index Immunitybio, Inc. Receives FDA Authorization to Conduct A Phase 1B/2 Open-Label Study
ImmunityBio, Inc. Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients Jun 11
Immunitybio, Inc. Expands Trials of T-Cell-Based Covid-19 Vaccine Candidate as A ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa May 26
Board Member recently sold €1.6m worth of stock May 26
FDA Authorizes ImmunityBio to Conduct Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell Platform in Solid Tumors May 18
Forecast to breakeven in 2025 May 16 Shareholder Returns 26CA DE Biotechs DE Market 7D 1.1% 2.1% -0.1% 1Y -31.3% -9.7% 7.4%
See full shareholder returns
Return vs Market: 26CA underperformed the German Market which returned 7.4% over the past year.
Price Volatility Is 26CA's price volatile compared to industry and market? 26CA volatility 26CA Average Weekly Movement 17.8% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 26CA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 26CA's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.
Show more ImmunityBio, Inc. Fundamentals Summary How do ImmunityBio's earnings and revenue compare to its market cap? 26CA fundamental statistics Market cap €1.89b Earnings (TTM ) -€565.87m Revenue (TTM ) €7.06m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 26CA income statement (TTM ) Revenue US$7.33m Cost of Revenue US$0 Gross Profit US$7.33m Other Expenses US$595.13m Earnings -US$587.79m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.84 Gross Margin 100.00% Net Profit Margin -8,016.83% Debt/Equity Ratio -131.0%
How did 26CA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/06 01:20 End of Day Share Price 2025/01/06 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ImmunityBio, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Kolbert D. Boral Capital LLC. Dingding Shi Jefferies LLC Joseph Catanzaro Piper Sandler Companies
Show 0 more analysts 